Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Clinical Impact of the Cell-of-Origin Classification and the MYC / BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

Staiger, Annette M., Ziepert, Marita, Horn, Heike, Scott, David W., Barth, Thomas F.E., Bernd, Heinz-Wolfram, Feller, Alfred C., Klapper, Wolfram, Szczepanowski, Monika, Hummel, Michael, Stein, Harald, Lenze, Dido, Hansmann, Martin-Leo, Hartmann, Sylvia, Möller, Peter, Cogliatti, Sergio, Lenz, Georg, Trümper, Lorenz, Löffler, Markus, Schmitz, Norbert, Pfreundschuh, Michael, Rosenwald, Andreas, Ott, German, for the German High-Grade Lymphoma Study Group · 2017 · Journal of Clinical Oncology

Abstract

Purpose: To explore the prognostic impact and interdependence of the cell-of-origin (COO) classification, dual expression (DE) of MYC and BCL2 proteins, and MYC, BCL2, and BCL6 translocations in two prospectively randomized clinical trials of patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Overall, 452 formalin-fixed paraffin-embedded samples from two prospective, randomized DLBCL trials (RICOVER-60, prospective, randomized study for patients > 60 years, all IPI groups; and R-MegaCHOEP, prospective, randomized study for patients ≤ 60 years with age-adjusted IPI 2,3) of the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the Lymph2Cx assay for COO classification, with immunohistochemistry for MYC and BCL2, and with fluorescent in situ hybridization for MYC, BCL2, and BCL6 rearrangements. Results: COO classification was successful in 414 of 452 samples. No significant differences with respect to COO (activated B-cell [ABC]–like DLBCL v germinal center B-cell [GCB]–like DLBCL) were observed in event-free survival, progression-free survival, and overall survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the RICOVER-60 trial. Also, no differences with respect to COO were observed in multivariable analyses adjusted for International Prognostic Index factors in event-free survival (hazard ratio [HR] of ABC-like disease v GCB-like disease, 1.0; 95% CI, 0.6 to 1.6; P = .93), progression-free survival (HR, 1.1; 95% CI, 0.6 to 1.8; P = .82), and overall survival (HR, 1.0; 95% CI, 0.6 to 1.8; P = .96). Similar results were observed in the R-MegaCHOEP trial. In patients treated with R-CHOP, DE status was associated with significantly inferior survival compared with nonDE within the GCB, but not within the ABC subgroup. DE status was associated with significantly inferior outcome compared with patients with ABC-like DLBCL without DE (5-year PFS rate, 39% [95% CI,19% to 59%] v 68% [95% CI, 52% to 85%]; P = .03) and compared with patients with GCB-like DLBCL without DE. When data from patients with nonDE were analyzed separately, the outcome of patients in the ABC subgroup was inferior to that of patients in the GCB subgroup (5-year PFS rate, 68% [95% CI, 52% to 85%] v 85% [95% CI, 74% to 96%]; P = .04). Conclusion: COO profiling in two prospective randomized DLBCL trials failed to identify prognostic subgroups, whereas dual expression of MYC and BCL2 was predictive of poor survival. Evaluation of prognostic or predictive biomarkers in the management of DLBCL, such as the COO, within prospective clinical trials will be important in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.70.3660

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 221

Metadata

Authors
Staiger, A. M., Ziepert, M., Horn, H., Scott, D. W., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Szczepanowski, M., Hummel, M., Stein, H., Lenze, D., Hansmann, M.-L., Hartmann, S., Möller, P., Cogliatti, S., Lenz, G., Trümper, L., Löffler, M., Schmitz, N., Pfreundschuh, M., Rosenwald, A., Ott, G., & for the German High-Grade Lymphoma Study Group
Venue
Journal of Clinical Oncology
Published
2017-08-01
Volume
35
Issue
22
Pages
2515-2526
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2614435853
Cited by
221
References
3
FWCI
19.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Impact of the Cell-of-Origin Classification and the MYC / BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. https://app.cochat.ai/papers/10.1200/jco.2016.70.3660
The paper
Staiger, A. M., Ziepert, M., Horn, H., Scott, D. W., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Szczepanowski, M., Hummel, M., Stein, H., Lenze, D., Hansmann, M.-L., Hartmann, S., Möller, P., Cogliatti, S., Lenz, G., Trümper, L., Löffler, M., . . . for the German High-Grade Lymphoma Study Group. (2017). Clinical Impact of the Cell-of-Origin Classification and the MYC / BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.70.3660

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.